High materiality8/10
Phathom Pharmaceuticals price target lowered to $14 from $18 at Barclays
Why it may matterVerify against the original reporting
Upside potential persists despite downgrade; target still above current price.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Barclays cuts PHAT target to $14; current price around $9.58. Upside remains based on target versus price.
- Barclays cuts target to $14; current price $9.58; upside remains.
Key facts
- 01
Target: $14
- 02
Posted price: $9.58
- 03
Analyst firm: Barclays
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.